# Biosplice Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biosplice-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.biosplice.com
- Total disclosed funding: $120M
- Latest round: Series B (Apr 15, 2021)
- Investors on record: 5

## About

Founded in 2020 and based in California, US, Biosplice Therapeutics, Inc. (Biosplice), formerly Samumed, LLC operates as a biotechnology company that develops therapeutics based on alternative pre-mRNA splicing for major diseases. In April 2021, the company received USD 120 million from  Eventide Asset Management, aMoon, SymBiosis II, Sands Capital, Verition Fund Management, and others.

The company offers small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing a process that enables a messenger RNA (mRNA) to direct the synthesis of different protein variants intended to treat major diseases in osteoarthritis, oncology, and neurology. 

Biosplice Therapeutics, Inc. plans to accelerate the development and launch of lorecivivint, a Phase 3 program in osteoarthritis.

## Funding rounds

- Series B, Apr 15, 2021, $120M — Verition Fund Management, Eventide Asset Management, Sands Capital Alternatives, aMoon, SymBiosis LLC

## Investors

- Verition Fund Management — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series B
- aMoon (https://capitalatlas.ai/funds/amoon) — Series B
- SymBiosis LLC — Series B